Eli Lilly's obesity drug retatrutide cuts sleep apnea episodes in trials
Juste les faits

Eli Lilly's obesity drug retatrutide cuts sleep apnea episodes in trials

Résumé

Two phase-III trials found that retatrutide significantly reduced obstructive sleep apnea events and, in many cases, eliminated the need for a breathing-assist device.

Eli Lilly reported that its obesity medication retatrutide lowered the frequency of obstructive sleep apnea (OSA) episodes in two recent clinical studies. The trials, embedded within larger phase-III programs, involved about 700 participants with obesity, some of whom also had type 2 diabetes. Participants receiving retatrutide experienced fewer apnea and hypopnea events compared with those given a placebo, and more than half of users in one study achieved remission or a downgrade to mild OSA, reducing reliance on positive airway pressure machines.

Retatrutide belongs to a new class of drugs that combine the actions of GLP-1, GIP and glucagon hormones. Earlier large-scale, double-blind, placebo-controlled trials have shown strong weight-loss effects, prompting expectations of regulatory approval in the near future. The OSA findings were published in the New England Journal of Medicine.

Researchers noted that while the drug’s impact was smaller among participants with both obesity and diabetes, it remained statistically significant. They also cautioned that retatrutide is unlikely to benefit individuals with OSA who are not overweight, as excess weight is only one of several risk factors. GLP-1-based therapies are already used as adjunct treatments for OSA, and another Eli Lilly drug, tirzepatide, received FDA approval for this indication in late 2024.

Source

Gizmodo

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.